I read the transcript after not absorbing the podcast! Hydroxychloroquine and Everolimus are the two drugs in the study, used separately or together, with an 80% rate of eliminating dormant cancer cells (found in bone marrow).

I was interested in the explanation that recurrence happens after 5 years for ER+ cancer, since cells don't wake up in that time. But for ER- they wake up earlier. That explains why risk goes up for ER+ after 5 years, but if you have ER_ you are pretty safe if you make it 5 years.

This really hit home:

"And I think this would really represent an important advance because up to this point surveillance has really been about watchful waiting, and I got into this because, you know, for gosh, 15 years I was taking care of patients and we’d get to the end of that initial treatment and they would say well, how do you know it worked, and what are we going to do now, and when am I having my scans? And I would say, look, I don’t really have a way to know that and I don’t really have a way to monitor you, and that’s very, very stressful for patients. "

Thanks.i finally found it. I wish these trials were for triple positive BC. The 2 mentioned are for ER+ HER2-.